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Abstract
BACKGROUND—Erythropoiesis-stimulating agents (ESAs), intravenous iron, and blood 
transfusion are used to treat anemia in both end-stage renal disease (ESRD) and cancer. However, 
anemia treatment patterns have not been described among ESRD patients undergoing 
hemodialysis with concurrent cancer, especially in the recent era of ESA-related safety concerns.
METHODS—We analyzed Medicare data from a cohort of hemodialysis patients diagnosed with 
incident cancer. We used multivariable generalized linear models to estimate trends and patterns 
in ESA use, iron use, transfusion use, epoetin alfa (EPO) dose, iron dose, and resulting 
hemoglobin levels (2000–2011).
RESULTS—Of 43,760 eligible patients, quarterly ESA use declined slightly from a peak of 
94.1% to 90.0%. Quarterly EPO dose increased from 2000 to 2004, then declined; quarterly 
hemoglobin levels followed a similar pattern. Iron use increased rapidly from 46.9% to 79.3%. 
Iron dose increased until 2010, then declined. There was an increase in quarterly transfusion use 
(6.3% to 11.7%) and mean number of transfusion days per year (1.4 to 1.8). Anemia treatment 
patterns varied by demographic/clinical subgroups, especially among patients receiving 
chemotherapy, who required higher ESA use, EPO dose, and frequency of transfusions.
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CONCLUSIONS—Despite safety concerns about ESAs in both the ESRD and cancer 
populations, the proportion of hemodialysis patients with cancer who used ESAs between 2000 
and 2011 remained extremely common. EPO dose and hemoglobin levels increased then 
decreased. Iron use, iron dose, and transfusions increased substantially. Future research examining 
the risk-benefit profile of different anemia management strategies in the dialysis population with 
cancer is needed.
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INTRODUCTION
Erythropoiesis-stimulating agents (ESAs) have been widely used for anemia management in 
both end-stage renal disease (ESRD) patients and cancer patients to increase hemoglobin 
levels, reduce the need for red blood cell transfusions, and alleviate anemia-related 
symptoms. After many years of escalating ESA use in both the ESRD population and the 
cancer population, anemia management patterns changed markedly in response to negative 
safety reports, product labeling changes, black box advisories, revised anemia management 
guidelines, and reimbursement changes.
In May 2004, the United States Food and Drug Administration (FDA) mandated the first of 
an increasingly restrictive series of product labeling changes for the ESA class of drugs in 
response to reports of increased mortality in patients with cancer.1 In March 2007, the FDA 
mandated the addition of a black-box warning for ESA drugs due to reports of increased risk 
of death and serious cardiovascular events in patients with chronic kidney disease and 
increased risk of tumor progression and/or death in patients with cancer when hemoglobin 
levels were greater than 12.0 g/dL.2 This advisory was followed by revisions of clinical 
guidelines for ESA use.3–5 Clinical guidelines have been regularly updated as emerging 
safety data has become available. Also in 2007, the Centers for Medicare and Medicaid 
Services published a National Coverage Decision to limit reimbursement for ESA 
administration and tie reimbursement to specific hemoglobin levels and time schedules.6 
Beginning in 2010, the FDA required that ESAs be prescribed to cancer patients under its 
risk evaluation and mitigation strategy program, which involves additional education for 
healthcare providers who prescribe and dispense ESAs as well as documentation that 
patients understand ESA-related risks.7 In January 2011, CMS implemented the ESRD 
prospective payment system wherein most aspects of the outpatient treatment of ESRD 
patients were combined into a single payment.8 Shortly after, in June 2011, the FDA 
approved a revised ESA label that removed a specific target for hemoglobin level.9
Several recent national studies conducted in both the cancer and chronic kidney disease 
populations have reported declines in ESA use, ESA dose, transfusion use, and hemoglobin 
levels and increases in iron use and iron dose.10–18 However, no information exists 
regarding trends in anemia treatment among patients with both ESRD and cancer.
A cancer diagnosis complicates anemia management in ESRD patients undergoing dialysis 
for many reasons. First, there are additional safety concerns associated with ESA treatment 
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in the cancer population including tumor progression, thromboembolic complications, and 
mortality.19,20 Beginning in 2003, eight randomized clinical trials in cancer patients reported 
increased risk of tumor progression and/or death among cancer patients treated with 
ESAs.21–29 The most recent meta-analyses of cancer patients demonstrated significant 
effects of ESAs on increased thromboembolic events and mortality but not on disease 
progression.30 Second, there are currently no formal guidelines for providers regarding 
appropriate usage of ESAs in ESRD patients with cancer.20 For patients undergoing dialysis, 
the United States recommendation is to initiate treatment when the hemoglobin level is less 
than 10 g/dL and to individualize dosing and use the lowest dose of ESA sufficient to reduce 
the need for transfusions.31 For cancer patients, the recommendations are similar except the 
ESA indication for treatment of anemia is restricted to patients undergoing 
myelosuppressive chemotherapy.32 Third, little is known regarding patterns of anemia 
management in dialysis patients with cancer. In this population, it remains unclear how 
anemia treatment has been affected by recent clinical and policy events.
The objectives of this study were to examine trends in anemia management in the U.S. 
hemodialysis population after the diagnosis of cancer. Using population-based data from the 
United States Renal Data System (USRDS), a national registry including all patients in 
Medicare’s ESRD program, we described patterns of use of ESAs, iron, and transfusions as 
well as resulting hemoglobin levels. We examined anemia management patterns within 
subgroups, including cancer site and chemotherapy use. We report trends from 2000 to 
2011, a time period that includes data before and after negative safety reports, product 




Using data from the USRDS, a national registry of patients in Medicare’s ESRD program, 
we identified all ESRD patients ≥ 18 years who received in-center hemodialysis between 
April 1, 1995 and December 31, 2011 with Medicare as their primary payer and both parts A 
and B coverage. We restricted the cohort to patients who received their first cancer diagnosis 
at least 9 months after dialysis initiation. This time period was to ensure stability in dialysis 
treatment modality (months 0–3 post-dialysis initiation),33 and to exclude prevalent cancer 
cases identified using Medicare claims (months 3–8 post-dialysis initiation), as previously 
described.34–37 Patients with a malignancy-related primary cause of ESRD or a history of 
kidney transplantation or HIV/AIDS were also excluded. We further restricted the cohort to 
patients with post-cancer diagnosis follow-up time between 2000 and 2011. This restriction 
ensured a similar distribution of incident and prevalent hemodialysis patients over time, 
which was necessary because EPO dosing has been documented to increase with longer time 
on dialysis.15
Incident Cancer Definitions
We identified incident site-specific cancers using International Classification of Diseases, 
9th revision, Clinical Modification (ICD-9-CM) diagnosis codes from inpatient and 
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outpatient Medicare claims (Supplemental Table 1), as previously described.34 The claims-
based algorithm used to define site-specific cancers required ≥ 2 ICD-9-CM diagnosis codes 
within 6 months, adapted from an algorithm (requiring ≥ 2 ICD-9-CM diagnosis codes 
within 2 months) validated in a Medicare population for identification of incident cancers 
including lung, colorectal, stomach, breast and lymphoma (sensitivity: range, 56% to 77%; 
specificity: ≥ 99%; positive predictive value: range, 56% to 77%).38 We extended the time 
period to 6 months between cancer diagnosis codes to allow for delays in health care 
encounters that may occur due to the high severity of illness characteristic of the ESRD 
population. Date of cancer onset was defined as the first date of a cancer-related diagnosis 
code in the claims data. In situ carcinomas were included for two sites (i.e., breast and 
bladder).39 Secondary tumors, benign tumors, and non-melanoma skin cancers were 
excluded. Only the first cancer diagnosis after dialysis initiation was included as an event.
Anemia Therapy Outcomes
Information on ESAs, iron, and hematocrit was identified from dialysis claims from the 
Medicare Part A institutional claims files and Medicare Part A and B claims. Information on 
transfusions was identified from Medicare Part A and B claims. The codes used to identify 
ESAs, iron, and transfusions are presented in Supplemental Table 2. Monthly outlier values 
were set to missing if outside the specified ranges (EPO dose, 500–700,000 units; 
hematocrit, 20–60 g/dL).15 Data were summarized by calendar quarter. We calculated the 
quarterly proportion of the study population treated with ESAs (epoetin alfa (EPO), 
darbepoetin alfa (DPO)) or iron. Mean EPO dose (units/month) was calculated as the 
quarterly sum of EPO doses divided by 3. DPO dose was excluded from the analysis due to 
major variation in annual missingness over the study period. Because most DPO use 
occurred in hospital-based facilities, these units were excluded from the EPO dose 
calculation to avoid under-ascertainment of total ESA dose. Iron dose (mg) was based on the 
HCPCS code for iron dextran, iron sucrose, ferric gluconate, or ferumoxytol, and number of 
units associated with each claim. Mean quarterly hemoglobin levels were calculated by 
dividing hematocrit levels by 3. We calculated the quarterly proportion of the study 
population that received transfusions, as well as the mean number of days per year that each 
patient received a transfusion.
Covariates
We obtained the following information from the USRDS patient file: first service date, sex, 
race, primary cause of ESRD. Information on ethnicity was obtained from the Medical 
Evidence file. For each calendar quarter, age at dialysis initiation and duration of dialysis 
(i.e., vintage) were calculated on the first date of the quarter by subtracting the first service 
date. We identified chemotherapy administration during each quarter using ICD-9-CM 
diagnosis and procedure codes, Healthcare Common Procedure Coding System (HCPCS) 
codes, and revenue codes (Supplemental Table 3).40,41
Statistical Analysis
We calculated descriptive statistics on the demographic and clinical characteristics of the 
population by year. We also described the annual distribution of cancer diagnoses by cancer 
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site. To describe trends in anemia treatment by calendar quarter, we used generalized linear 
models to generate unadjusted and adjusted estimates. Specifically, we used logistic 
regression models to calculate quarterly estimates of the proportion of patients that used 
ESAs, iron, or transfusion, linear regression models to calculate mean quarterly estimates of 
EPO dose (units/month), iron dose (mg/quarter) and hemoglobin levels (g/dL), and Poisson 
regression models to calculate estimates of the mean number of transfusion days per year. 
Since EPO dose and hematocrit levels were only reported with the administration of ESAs, 
these analyses were restricted to patients who received ESAs at least once during the 
quarter. Calendar quarter or year was treated as a categorical variable in the models to relax 
the assumption of linearity. The results section presents plots of the adjusted estimates for 
ESA use, iron use, transfusion use, EPO dose, iron dose, number of transfusion days, and 
hemoglobin levels, which are population marginal means that account for changes over time 
in demographic (age, sex, race, ethnicity) and clinical characteristics (primary cause of 
ESRD, dialysis vintage).42 The trend lines and corresponding 95% confidence intervals 
were calculated as a smoothed conditional mean of the quarterly or yearly adjusted 
estimates. We stratified estimates by cancer site and chemotherapy use, as well as several 
additional demographic and clinical characteristics. We further stratified the analyses by 
using three categories of cancer site: a) all cancer sites; b) the most common solid tumors in 
our study population (i.e., cancers of the prostate, female breast, colon/rectum, lung/
bronchus, kidney/renal pelvis, bladder, and pancreas); and c) hematologic malignancies (i.e., 
Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), leukemia, and myeloma). We 
performed complete case analyses since covariate missingness was less than 1% (i.e., 
ethnicity (n=156)). SAS software, version 9.3 (Cary, NC) and R, version 0.98.507 were used 
to perform analyses.43
RESULTS
A total of 43,760 incident cancer patients receiving hemodialysis met eligibility 
requirements for this study. Demographic and clinical characteristics are presented for 
selected years (i.e., 2000, 2002, 2004, 2007, 2009, and 2011) in Table 1. The number of 
eligible patients per year increased from 5,081 in 2000 to 11,898 in 2011. Over time, 
patients were more likely to be black, Hispanic, or have diabetes as the primary cause of 
ESRD. Between 2000 and 2011, mean age at dialysis initiation decreased from 67.9 to 65.7 
years, whereas mean age at cancer diagnosis remained constant. The median duration of 
dialysis at cancer diagnosis was 2.1 years (IQR, 1.3–3.6). The median length of follow-up 
after cancer diagnosis was 1.0 year (IQR, 0.3–2.4), and 19.2% of patients remained in 
follow-up at 3 years post-cancer diagnosis.
The distribution of cancer diagnoses by cancer site and year is presented in Supplemental 
Figure 1 and Supplemental Table 4. The most frequently diagnosed cancer sites were 
prostate, colorectal, and female breast. Cancers of the kidney/renal pelvis had the most 
notable increase between 2000 and 2011, from 6.5% to 11.2% of diagnosed cancers.
Over the study period, the quarterly proportion of patients that received ESAs declined 
slightly, from a peak of 94.1% in early 2002 to 90.0% in late 2011. Use of EPO decreased 
from 94.1% to 85.4% between mid-2002 and mid-2007, and then remained relatively stable. 
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Use of DPO increased from 0.0% to 7.9% between 2003 and 2007, and then decreased to 
5.2% by 2011 (supplemental figure 2). ESA use varied by cancer site. On average, quarterly 
ESA use was lower among patients with hematologic malignancies compared to patients 
with solid tumors (92.0% vs. 93.3%) (figure 1, supplemental figures 3–4).The quarterly 
proportion of patients that received intravenous iron increased gradually from 46.9% in late 
2001 to 79.3% in mid-2011, and then declined to 73.9% by late 2011. On average, quarterly 
iron use was lower among patients with hematologic malignancies compared to patients 
with solid tumors (62.4% vs. 66.5%) (figure 1, supplemental figures 3–5).
Among patients receiving EPO, the mean EPO dose increased from approximately 66,000 
units/month in early 2001 to 83,000 units/month in mid-2004, and then declined to 52,000 
units/month by late 2011. Patients with hematologic malignancies used a higher mean EPO 
dose compared to patients with solid tumors (~86,000 vs. 72,000 units/month) (figure 2, 
supplemental figures 3–4).
Among patients receiving iron, the mean dose increased from approximately 520 mg in 
2000 to 830 in 2010, and then declined to 680 mg in 2011. Iron dose did not vary 
substantially by cancer site (figure 2, supplemental figures 3–4).
Mean quarterly hemoglobin levels followed a similar pattern to EPO dose. Among patients 
receiving ESAs, hemoglobin levels increased from 11.3 g/dL in early 2000 to 11.9 g/dL in 
mid-2004, and then declined to 10.7 g/dL by late 2011. Patients with hematologic 
malignancies had slightly lower mean quarterly hemoglobin levels compared to patients 
with the most common solid tumors (11.4 vs. 11.6 g/dL) (figure 2, supplemental figures 3–
4).
The quarterly proportion of patients that received transfusions increased from 6.3% in 
mid-2000 to 11.7% in mid-2011. Use of transfusion was more common among patients with 
hematologic malignancies compared to patients with solid tumors (quarterly mean, 12.0% vs 
8.2%) (figure 3, supplemental figures 3–4). Among patients who received transfusion, the 
mean number of transfusion days per year increased steadily from 1.5 to 1.9 days between 
2000–2011, with a steeper increase among patients with hematologic malignancies (1.6 to 
2.6 days) compared to patients with solid tumors (1.5 to 1.8 days) (figure 3).
The quarterly proportion of chemotherapy receipt decreased from 6.3% in quarter 1 of 2000 
to 5.8% in quarter 4 of 2011. Supplemental figure 6 presents quarterly trends in anemia 
treatment by chemotherapy use. Compared to cancer patients who did not receive 
chemotherapy, patients who received chemotherapy had higher mean quarterly ESA use 
(93% vs. 96%) and higher mean EPO dose (~72,000 vs. 95,000 units/month). Almost twice 
as many patients on chemotherapy received quarterly transfusions compared to patients who 
did not receive chemotherapy (15.8% vs 8.3%). Mean quarterly hemoglobin levels were 
lower among patients who received chemotherapy compared to patients who did not receive 
chemotherapy (11.3 vs. 11.6 g/dL).
Analyses stratified by demographic characteristics revealed several meaningful differences 
in anemia treatment patterns (supplemental figures 7–12). ESA use was lower among 
patients who were male, non-African American, receiving dialysis for <2 years, or with 
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primary cause of ESRD due to polycystic kidney disease. EPO dose was lower among 
patients who were older, non-African American, Hispanic, receiving dialysis for <2 years, or 
with primary cause of ESRD due to polycystic kidney disease. Iron use was lower among 
patients who were older or other race. Iron dose was lower among patients who were older, 
female, non-African American, or receiving dialysis for <2 years. Transfusion use was lower 
among patients who were non-Hispanic, receiving dialysis for ≥2 years, or with primary 
cause of ESRD due to polycystic kidney disease. Hemoglobin levels did not vary 
substantially by subgroups.
DISCUSSION
In this study of anemia treatment patterns among U.S. hemodialysis patients diagnosed with 
incident cancer, we observed high and near-constant use of ESAs. Compared to previously 
reported trends in the population of hemodialysis patients without cancer, ESA use remained 
higher and more constant (i.e., >90%) but EPO dosing and hemoglobin level estimates were 
similar (i.e., increased until 2004 and 2006, respectively, and then declined steadily). We 
observed significant variability in ESA use and EPO dosing across subgroups. Specifically, 
ESA use was lower among patients who were male, non-African American, had been 
receiving dialysis for less than 2 years, or had polycystic kidney disease as cause of ESRD. 
And notably, average EPO doses were substantially higher among patients with 
hematological malignancies as well as patients receiving chemotherapy compared to patients 
with solid tumors and no chemotherapy, respectively. Additionally, we noted a similarly 
steady increase in iron use, iron dose, and transfusion use.
To our knowledge, this is the first study in the hemodialysis population with incident cancer 
examining trends in anemia management. In contrast to our findings of constant ESA use 
over time in our hemodialysis population with cancer, the cancer literature documents a 
dramatic decrease in ESA use (i.e., both EPO and DPO) among cancer patients in the years 
surrounding the 2007 FDA black-box warning. Among VA cancer patients, ESA use 
plateaued in late 2003 and sharply declined from 38% (2006) to 12% (2008) among colon 
cancer patients and from 23% (2006) to 5% (2008) among lung cancer patients.10 Another 
study of cancer patients undergoing chemotherapy across 39 sites in seven states reported a 
decline from 41% to 30% between 10-month intervals before and after the 2007 FDA black-
box warning.12 Two studies of cancer patients treated at MD Anderson Comprehensive 
Cancer Center reported decreases in ESA use between 2006 and 2008 of 17% to 5% and 4% 
to 1%.11,13
Although ESA use remained relatively constant among dialysis patients with cancer over the 
study period, we observed an 8.7% decrease in EPO use between 2002 and 2007 and a 
corresponding increase in DPO use. Indeed, the timing and magnitude of the decline in EPO 
use follows a pattern similar to that previously documented in the hemodialysis 
population.15 In both studies, EPO use declined steeply after the emergence of ESA-related 
safety concerns and has continued to decline. Compared to the larger hemodialysis 
population, our hemodialysis population with cancer had slightly lower EPO use and 
hemoglobin levels, slightly higher EPO dosing, and similar iron use and dosing. Among 
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hemodialysis patients with cancer, ESA use remains high however the administered dose has 
declined substantially for the majority of these patients.
After the 2011 CMS implementation of the new bundled prospective payment system, we 
observed a decrease in ESA use, EPO dose, iron dose, and hemoglobin levels and an 
increase in iron use and transfusion use.8 These results were consistent with reports from 
other populations.17,44 It will be important to monitor these trends as we move forward.
Current guidelines conflict regarding appropriate treatment in the subgroup of dialysis 
patients with cancer who do not receive chemotherapy. The guidelines for dialysis patients 
are similar to the guidelines for cancer patients, except that the ESA indication for treatment 
of anemia is restricted to cancer patients undergoing myelosuppressive chemotherapy.31,32 
These evidence-based guidelines were influenced by studies of cancer patients that 
consistently reported modification of mortality risk associated with ESAs by chemotherapy 
use.20 As expected, we observed that patients who did not receive chemotherapy had higher 
hemoglobin levels and less intensive anemia treatment, including lower ESA use, EPO dose, 
and transfusion use, compared to patients that received chemotherapy. Yet, the common 
ESA use in this subgroup of patients not receiving myelosuppressive chemotherapy is 
noteworthy. These findings highlight discrepancies between guideline-recommended 
therapy and actual practice.
Transfusion avoidance remains an important goal due to dangerous transfusion-related 
complications including hyperkalemia, fluid overload, iron overload and allosensitization.45 
Between 2000 and 2011, we observed an increasing proportion of hemodialysis patients 
with cancer that received transfusions and an increasing mean number of transfusion days 
per year. Since transfusion avoidance provided the formal reason for the original approval 
and use of ESAs, it seems paradoxical that transfusion use is increasing despite constant 
ESA use.46 One likely explanation for the increase in transfusion use is the recent paradigm 
shift towards lower ESA dosing and lower hemoglobin levels. A recent study reported that 
Medicare hemodialysis patients with 3-month mean hemoglobin levels <10 g/dL received 
transfusions at a rate approximately 4 times higher than the rate for patients with 
hemoglobin levels maintained at ≥10 g/dL. Although transfusion rates among patients with 
hemoglobin levels <10 and ≥10 g/dL remained relatively constant between 1999 and 2010, 
the proportion of patients with hemoglobin levels <10 g/dL began to increase after 2006, and 
consequently, the absolute number of patients receiving transfusions also began to 
increase.16
Our findings are subject to several limitations. First, our results may not be generalizable to 
non-dialysis patients with chronic kidney disease, patients on peritoneal dialysis, patients 
with a non-Medicare primary payer, or patients who died within 9 months of dialysis 
initiation. Second, claims-based cancer definitions are commonly used in cancer research, 
but have not been validated in the ESRD population. Third, we cannot exclude the 
possibility of misclassifying prevalent cancer cases as incident cases. However, 
identification of prevalent cancer cases during the 6-month baseline period minimized the 
possibility of misclassification. Fourth, use of claims-based definitions made it impossible to 
determine whether cancers identified as incident cases were truly new primaries, metastases, 
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or histories of cancer that were miscoded as new primaries. Fifth, we analyzed the number 
of transfusion days per year rather than the actual number of transfusions, because all 
transfusions administered on any single day are covered by a single procedural code. Sixth, 
ESA claims are provided from outpatient dialysis claims but not from hospital claims. Since 
ESRD patients require several hospital days per year on average, this missing data may yield 
lower estimates of ESA use and dose. Lastly, we may be missing a small proportion of 
chemotherapy use due to lack of access to some specific chemotherapy agent codes (i.e., 
National Drug Codes).
Strengths of our study include more than a decade of data on the large and representative 
population of U.S. ESRD patients diagnosed with cancer after hemodialysis initiation. The 
large sample size allowed the novel characterization of anemia management patterns within 
subgroups, including cancer site and chemotherapy use.
In conclusion, our results suggest that ESA and iron use is common in hemodialysis patients 
with cancer, and trends in dosing have been similar to those in the overall hemodialysis 
population. The potential risks associated with ESA and iron use must be balanced with 
known benefits, such as alleviating anemia-related symptoms and transfusion avoidance. 
Further research is needed to better understand the risks and benefits of anemia therapy in 
the population of dialysis patients with cancer.
Supplementary Material
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Mean quarterly ESA use and iron use for a) all cancer sites; b) most common solid tumors in 
our study population (i.e., cancers of the prostate, female breast, colon/rectum, lung/
bronchus, kidney/renal pelvis, bladder, and pancreas); and c) hematologic malignancies (i.e., 
Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia, and myeloma). Quarterly data 
points were adjusted for age, sex, race, ethnicity, cause of ESRD, and dialysis vintage. 
Trend lines represent smoothed conditional means.
Butler et al. Page 13














Mean quarterly ESA dose, iron dose, and hemoglobin levels for a) all cancer sites; b) most 
common solid tumors in our study population (i.e., cancers of the prostate, female breast, 
colon/rectum, lung/bronchus, kidney/renal pelvis, bladder, and pancreas); and c) 
hematologic malignancies (i.e., Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia, 
and myeloma). Quarterly data points were adjusted for age, sex, race, ethnicity, cause of 
ESRD, and dialysis vintage. Trend lines represent smoothed conditional means. For EPO 
Butler et al. Page 14













dose, patients treated at a hospital-based facility were excluded to remove the possibility of 
simultaneous treatment with EPO and DPO.
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Mean quarterly use of blood transfusions and mean number of blood transfusion days per 
year among patients who received blood transfusions, by cancer site for 1) all cancer sites; 
2) most common solid tumors in our study population (i.e., cancers of the prostate, female 
breast, colon/rectum, lung/bronchus, kidney/renal pelvis, bladder, and pancreas); and 3) 
hematologic malignancies (i.e., Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia, 
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and myeloma). Data points were adjusted for age, sex, race, ethnicity, cause of ESRD, and 
dialysis vintage. Trend lines represent smoothed conditional means.
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